Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Sales of Zoledronic Acid for use in oncology-related bone conditions hit $1.5bn in 2010Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report.
By: Joe Walsh According to the report, Novartis has successfully complied with the measures in agreed paediatric investigation plans (PIP) and has been awarded 6 month extensions to the terms of the SPCs, giving an expiry of May 2013. National patent term extensions have also been granted in Australia and the US with expiries of November 2012 and May 2013 respectively. In all major territories where Zoledronic Acid has been marketed, the data and marketing exclusivity have already expired and are not a factor for generic competition. In the US, tentative FDA approvals for generic Zoledronic Acid have been granted to Apotex, Bedford, Emcure, Hospira, Pharmaceuticals International, Pharmaforce, Sun and Teva. Read more about the report “Zoledronic Acid: Comprehensive Patent Search” is available from Report Buyer at: http://www.reportbuyer.com/ Reportbuyer.com Product Code: GEW01101 Report Buyer http://www.reportbuyer.com/ # # # About Piribo. Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|